Is empagliflozin (Jardiance) appropriate for a patient with an estimated glomerular filtration rate of 31 mL/min/1.73 m² who is taking atorvastatin 20 mg?

Jardiance (Empagliflozin) is Appropriate for eGFR 31 mL/min/1.73 m²

Yes, Jardiance can be initiated at an eGFR of 31 mL/min/1.73 m² for cardiovascular and kidney protection, though not for glycemic control alone. The concurrent use of atorvastatin 20 mg poses no contraindication or interaction concern.

Guideline-Based Recommendation

The 2022 ADA/KDIGO consensus guidelines explicitly recommend SGLT2 inhibitors with proven kidney or cardiovascular benefit for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 1. Your patient with eGFR 31 falls within this range (Stage 3b CKD: 30-44 mL/min/1.73 m²).

Dosing at This eGFR Level

• Start with empagliflozin 10 mg daily 1
• The FDA label states initiation is not recommended below eGFR 30 for glycemic control, but heart failure indications allow initiation down to eGFR 20 2
• The 2024 KDIGO guidelines upgraded this to a 1A recommendation for eGFR ≥20 mL/min/1.73 m² 3

Critical Context for Your Patient

Glucose-lowering efficacy diminishes at this eGFR level, but cardiovascular and kidney benefits are preserved 1. This is crucial: you're prescribing empagliflozin primarily for:

• Reducing cardiovascular death and heart failure hospitalization
• Slowing CKD progression
• NOT primarily for glycemic control at eGFR 31

Evidence Supporting Use at eGFR 31

The EMPA-KIDNEY trial enrolled patients with eGFR as low as 20 mL/min/1.73 m² and demonstrated a 28% reduction in kidney disease progression or cardiovascular death 4. The EMPEROR trials showed consistent efficacy and safety down to eGFR 20 1, 5. Subgroup analyses from CREDENCE and DAPA-CKD trials with baseline eGFR <30 showed consistent benefits 1.

Atorvastatin Compatibility

There are no drug interactions between empagliflozin and atorvastatin. Both medications are appropriate at this eGFR level:

• Atorvastatin requires no dose adjustment for renal impairment
• The combination is commonly used and recommended for cardiovascular risk reduction in diabetic CKD patients

Monitoring and Safety Considerations

Expected Initial eGFR Dip

• Expect a reversible 2-5 mL/min/1.73 m² decline in eGFR within the first 4 weeks 1
• This is hemodynamic, not nephrotoxic—do not discontinue unless other complications arise
• Real-world data shows 21.6% experience >10% eGFR dip, but most recover by 6 months 6

Key Monitoring Parameters

• Recheck eGFR and electrolytes at 1 month, then every 3-4 months 1
• Monitor for volume depletion (especially if on diuretics)
• Assess for genital mycotic infections (6% incidence) 1
• Educate about ketoacidosis symptoms (rare but serious) 2

When to Hold Empagliflozin

• During acute illness, surgery, or prolonged fasting 1, 3
• If symptomatic hypotension develops
• If ketoacidosis suspected (even with normal glucose)

When to Continue Despite Low eGFR

Once initiated, continue empagliflozin even if eGFR falls below 30 or even below 20, unless dialysis is initiated or intolerance develops 1, 3. The CREDENCE and DAPA-CKD protocols specifically allowed continuation below initiation thresholds 1.

Common Pitfalls to Avoid

1. Don't discontinue for the initial eGFR dip—this is expected and protective long-term
2. Don't avoid initiation thinking "eGFR is too low"—guidelines now support use down to eGFR 20
3. Don't expect robust glucose lowering—the primary benefits at this eGFR are cardiovascular and renal protection
4. Don't forget sick day rules—hold during acute illness to prevent ketoacidosis

Contraindications at This eGFR

Empagliflozin is contraindicated only in patients on dialysis 2. Your patient at eGFR 31 is well above this threshold.